Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 5/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115276 | 0.83 | ERN1 (0.31) | ERN1 | |
| SCHEMBL4120606 | 0.81 | ALOX15 (0.36) | ERN1 | |
| SCHEMBL28173580 | 0.79 | CA1 (0.37) | KMT2APOLBMEN1KDM4EABL1 | |
| SCHEMBL21823051 | 0.78 | ERN1 (0.37) | KMT2AERN1POLBMEN1MCL1 | |
| SCHEMBL4121937 | 0.76 | ERN1 (0.50) | KMT2AERN1MEN1MCL1KDM4E | |
| SCHEMBL4132597 | 0.73 | CYP1A2 (0.39) | KMT2AERN1MEN1KDM4EMAPT | |
| SCHEMBL3639794 | 0.73 | POLB (0.51) | KMT2AERN1POLBKDM4E | |
| SCHEMBL29025470 | 0.71 | CYP3A4 (0.50) | KMT2APOLBMEN1MCL1ABL1 | |
| SCHEMBL11557280 | 0.71 | TP53 (0.44) | KMT2AMEN1 | |
| SCHEMBL4376307 | 0.69 | ERN1 (0.58) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | BAYER CROPSCIENCE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| EP-1883622-A1 | SUBSTITUTED ARYL OXIMES | Bayer CropScience Aktiengesellschaft (DE) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007090434-A1 | SUBSTITUTED ARYL OXIMES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | CYP1A1, PRDX1, CYP1A2 | KMT2A 796/4885ERN1 961/4885MAOA 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.